Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

Deborah A. Katza Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, IL, USACorrespondence[email protected]

Joan D. Morrisb Amgen Inc, Thousand Oaks, CA, USA

Michael P. Chuc Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada

Kevin A. Davidd Rutgers Cancer Institute of New Jersey, Rutgers Wood Johnson Medical School, New Brunswick, NJ, USA

Catherine Thieblemonte APHP, Hôpital Saint-Louis, Hemato-Oncology Unit Paris, France;f Diderot University, Paris, France

Nicholas J. Morleyg Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Sharif S. Khanh Hematology & Oncology, Bon Secours St. Francis, Greenville, SC, USA

Andreas Viardoti Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany

Alejandro Martín García-Sanchoj Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain

Guillermo Rodríguez-Garcíak Servicio de Hematología, Hospital Virgen del Rocío, Seville, Spain

Mariana Bastos-Oreirol Haematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Seung Tae Leem Division of Hematology/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA

William Kormanyb Amgen Inc, Thousand Oaks, CA, USA

Yuqi Chenb Amgen Inc, Thousand Oaks, CA, USA

Hansen L. Wongn Amgen Inc, South San Francisco, CA, USA

Abraham A. Andersonb Amgen Inc, Thousand Oaks, CA, USA

Yuliya Katlinskayan Amgen Inc, South San Francisco, CA, USA

Ariel A. Avilionn Amgen Inc, South San Francisco, CA, USA

Tian Daib Amgen Inc, Thousand Oaks, CA, USA

Eva González-Barcao Hematology, IDIBELL, Institut Català d'Oncologia, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

Your download is now in progress and you may close this window